�й�ҽѧ��ѧԺƤ�����о��� �Ͼ�ҽ��ԺƤ���� �Ͼ�ҽ��ԺƤ����

��ɳ��������һ�������࿹���ҩ������Ҫ�����������ù��������������ӺϾ��ȶ�������нϺõĿ������ԡ��ٴ��о���������������ȱ��Ļ��ߣ���ɳ�������Ч���ڷ�����������������ù��B�ȿ����ҩ����Ŀǰ�ٴ����������Ⱦ������������Ⱦ��Ϊ��ǰ;�Ŀ����ҩ�ÿ�οڷ���ɳ����200 mg��ÿ��3�ο�����һ���������Ⱦ�����������ص������Ⱦ��ÿ��800 mg����2 ~ 4�οڷ����䲻����Ӧ��Ҫ�з��ȡ���к�����ġ�Ż�º�ͷʹ�����ڲ�ɳ������һ���ĸι����𺦣��ᵼ�±����ᰱ��ת��ø�͵��������ߣ���ˣ������Ƶ�ͬʱ������ι��ܡ�

Posaconazole is a new triazole antifungal agent. It is structurally related to itraconazole and has high activity against Candida spp., Aspergillus spp., Cryptococcus neoformans, zygomycetes and other filamentous fungi. It has been suggested that the antifungal effect of posaconazole is superior to fluconazole, itraconazole, amphotericin B in immunocompromised patients. At present, it is the most perspective antifungal agent, especially in the treatment of deep fungal infection. Oral posaconazole of 200 mg thrice daily is effective against common fungal infection, while a daily dosage of 800 mg in two to four divided doses is required for the control of severe fungal infection. Posaconazole should be given with food or a nutritional supplement to enhance absorption. The most common side effects reported with posaconazole are fever, diarrhea, nausea, vomiting, and headache. Elevated liver enzymes, hyperbilirubinemia, and hepatocellular damage have been reported in clinical trials, hence, these laboratory indices should be monitored during treatment with posaconazole.